GSK - GlaxoSmithKline plc

NYSE - NYSE Delayed Price. Currency in USD
40.87
+1.26 (+3.18%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close39.61
Open40.42
Bid40.60 x 4000
Ask40.90 x 1000
Day's Range40.36 - 40.90
52 Week Range34.52 - 42.36
Volume4,203,748
Avg. Volume2,371,034
Market Cap99.18B
Beta (3Y Monthly)0.56
PE Ratio (TTM)46.23
EPS (TTM)0.88
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.98 (4.99%)
Ex-Dividend Date2018-08-09
1y Target Est44.30
Trade prices are not sourced from all markets
  • A Performance Overview of JNJ’s Beauty and OTC Businesses
    Market Realist2 days ago

    A Performance Overview of JNJ’s Beauty and OTC Businesses

    Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.

  • Better Buy: GlaxoSmithKline plc vs. Eli Lilly
    Motley Fool3 days ago

    Better Buy: GlaxoSmithKline plc vs. Eli Lilly

    Which stock is a better bet in an uncertain market?

  • GlobeNewswire4 days ago

    NeuroMetrix Reports Q3 2018 Financial Results

    WALTHAM, Mass., Oct. 17, 2018 -- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2018. The Company.

  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance6 days ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • A Financial Overview of Bausch Health in October
    Market Realist9 days ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

  • How Analysts View Bausch Health in October
    Market Realist9 days ago

    How Analysts View Bausch Health in October

    In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist10 days ago

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • A Closer Look at Novartis’s Innovative Medicines Segment
    Market Realist11 days ago

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

  • How Novartis’s Businesses Have Been Performing
    Market Realist11 days ago

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • A Look at Novartis’s Valuation on October 9
    Market Realist12 days ago

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.

  • Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
    American City Business Journals13 days ago

    Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area

    Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.

  • Merck Reports Positive Efficacy Data from Phase III HIV Study
    Zacks16 days ago

    Merck Reports Positive Efficacy Data from Phase III HIV Study

    Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.

  • Gilead Announces Positive Data From Ongoing Biktarvy Study
    Zacks16 days ago

    Gilead Announces Positive Data From Ongoing Biktarvy Study

    Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.

  • Analyzing Seattle Genetics’ Key Collaborations
    Market Realist16 days ago

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries. Adcetris was approved in Japan for treating frontline Hodgkin lymphoma. Seattle Genetics has a global collaboration with Takeda Pharmaceutical (TKPYY) to develop and commercialize Adcetris. While Seattle Genetics retains rights for the drug in the United States and Canada, Takeda has the rights for the drug in the rest of the world. Takeda pays Seattle Genetics a royalty.

  • J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
    Zacks17 days ago

    J&J's Phase III Data Shows Switch to its HIV Drug Beneficial

    Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.

  • GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
    Market Realist17 days ago

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.

  • The Wall Street Journal18 days ago

    [$$] Boston Pharma Adds to War Chest in Pacts With Novartis, GlaxoSmithKline

    Boston Pharmaceuticals Inc., a startup backed with a $600 million funding commitment from a single investor, is bulking up its portfolio of potential medications. PLC to add to its portfolio, securing three anti-infective programs from Novartis and five products from GSK, including drugs that could treat acne and irritable bowel syndrome.

  • Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018
    Market Realist18 days ago

    Mergers and Acquisitions in the Pharmaceuticals Sector in Q3 2018

    The US Pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists the recent mergers and acquisitions in the pharmaceuticals sector.

  • 6 of the Best Dividend Stocks Outside the U.S.
    InvestorPlace18 days ago

    6 of the Best Dividend Stocks Outside the U.S.

    In this day and age, dividend investors looking for high-dividend stocks shouldn’t limit themselves to U.S. companies only. Some of the best dividend stocks over time have been foreign issuers. And that’s still the case at the moment.

  • Why Dynavax Technologies Corporation Stock Struggled in September
    Motley Fool18 days ago

    Why Dynavax Technologies Corporation Stock Struggled in September

    Dynavax's shares kept losing ground last month, but a turnaround could be close at hand.

  • Reuters19 days ago

    GSK resumes some doctor payments, backtracking on blanket ban

    GlaxoSmithKline (GSK.L), which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances. Drugmakers have long used so-called key opinion leaders to promote the benefits of their products to other prescribing physicians and the decision to abandon this strategy was questioned by a number of analysts. GSK's new updated policy on working with healthcare professionals will now permit payments to global experts who speak about the science behind novel new medicines.

  • Reuters19 days ago

    GSK resumes some doctor payments, backtracking on blanket ban

    GlaxoSmithKline, which five years ago stopped paying doctors for promoting its drugs, said on Tuesday it would allow such payments once again in limited circumstances. Drugmakers have long used so-called key opinion leaders to promote the benefits of their products to other prescribing physicians and the decision to abandon this strategy was questioned by a number of analysts. GSK's new updated policy on working with healthcare professionals will now permit payments to global experts who speak about the science behind novel new medicines.

  • A Look at GlaxoSmithKline’s Consumer Healthcare Business
    Market Realist19 days ago

    A Look at GlaxoSmithKline’s Consumer Healthcare Business

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes the consumer healthcare portfolio including oral health products, wellness products, nutrition, and skin health products. The consumer healthcare segment reported revenues of ~1.8 billion pounds during the second quarter of 2018, a 3% increase in operating revenues.

  • How GlaxoSmithKline’s Vaccines Business Has Performed Recently
    Market Realist19 days ago

    How GlaxoSmithKline’s Vaccines Business Has Performed Recently

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, shingles vaccines, and established vaccines. The vaccines segment reported revenues of ~1.3 billion pounds during the second quarter of 2018, a 13% increase in YoY revenues. The growth includes a 16% increase in operating revenues offset by a 3% negative impact of foreign exchange during the quarter.